Celldex Therapeutics, Inc. — Director's Dealing 2009

Jan 8, 2009

SEC Form 4 — Statement of Changes in Beneficial Ownership

Issuer: Celldex Therapeutics, Inc. (CLDX)
CIK: 0000744218
Period of Report: 2009-01-06

Reporting Person: Davis Thomas Andrew (Sr. VP & CMO)

Non-Derivative Transactions

Date	Security	Code	Shares	Price	A/D	Holdings After	Ownership
2009-01-06	Common Stock	A	5868	—	Acquired	5868	Direct

Derivative Transactions

Date	Security	Exercise Price	Code	Shares	A/D	Expiration	Underlying	Ownership
2009-01-06	Incentive Stock Option	$8.52	A	76400	Acquired	2019-01-06	Common Stock (76400)	Direct

Footnotes

F1: On January 6, 2009, the Company granted 5,868 shares of Company common stock (in the form of unrestricted stock awards under the Plan) as a special bonus relating to management's performance with respect to the Merger and the integration efforts following the Merger.

F2: 25% of the options vest on Janaury 6, 2010 and the remainder vest quarterly (in equal amounts) on the last day of the subsequent 12 quarters.